Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Influenza
New influenza research from D.I. Bernstein et al outlined
April 30th, 2008
"Influenza A H5N1 viruses pose a significant threat to human health. We conducted a multicenter, randomized, double-blind study in 394 healthy adults," scientists in the United States report. "Subjects were randomly assigned to receive 2 intramuscular doses of either saline placebo; influenza A/Vietnam/1203/2004(H5N1) vaccine alone at 45, 30, or 15 mu g per dose; vaccine at 15 or 7.5 mu g per dose with MF59; or vaccine at 30, 15, or 7.5 mu g per dose with aluminum hydroxide. Subjects were followed up for safety and blood samples were obtained to determine antibody responses. The vaccine formulations were well tolerated but local adverse effects were common; the...
Source: Vaccine Weekly (2008-04-30)
|
